Max Healthcare Institute Limited (MAXHEALTH) share price and analysis
MAXHEALTH last traded at ₹1,030.90 (+2.08%) on the NSE. Market cap ₹1,00,340 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 4.6/10 (Average)
- Valuation: 2.1/10
- Profitability: 6.1/10
- Growth: 5.0/10
- Financial health: 5.8/10
- Price trend: 4.2/10
Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): No clear edge. Signals conflict. Sit it out or keep positions small.
Strengths of MAXHEALTH
- Revenue growth (YoY) (+20.3%): Sales are growing fast.
- Debt / equity (0.33): Comfortable debt level.
- Long-term trend (+2.1% vs 200-DMA): Just above its 200-day average. Still an uptrend, but not by much.
- Net profit margin (15.1%): Healthy profit margins.
- 52-week range (13% below high): In the upper half of its 52-week range.
- Volatility (1Y) (27% annualised): Below-average volatility.
Weaknesses of MAXHEALTH
- Valuation (P/E) (P/E 73.0 vs sector 41.1): Expensive at 1.8× the sector median P/E. High expectations are already priced in.
- Profit growth (YoY) (-15.5%): Profits are falling sharply.
- 50-DMA vs 200-DMA (-7.0% gap): 50-day average is below the 200-day (death-cross setup), so medium-term momentum is down.
- 6-month performance vs Nifty 50 (-1.8% vs +7.4%): Lagging the Nifty 50.
- Momentum (RSI 14) (RSI 76): Overbought (RSI above 75). The rally is stretched and a pullback is likely before the next leg up.
- Current ratio (0.84): Tight liquidity: short-term liabilities exceed short-term assets.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 73.0 | Expensive vs peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 45.0 | Profits expected to grow | below today's P/E (73.0) and near 41 |
| Price / book | 8.86 | High | 2–6 |
| EPS (TTM) | ₹14.13 | Profitable | above ₹0 |
| Return on equity | 12.8% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.33 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 15.1% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 21.4% | Strong | 20%+ strong, below 10% thin |
| Revenue growth | +20.3% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | -15.5% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.20% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 0.84 | Tight | 1.5+ (below 1 is tight) |
| 52W high | ₹1,185.40 | 13% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹797.00 | Price is 29% above it | |
| 50-DMA | ₹939.19 | Price 9.8% above | price above it = short-term uptrend |
| 200-DMA | ₹1,009.80 | Price 2.1% above | price above it = long-term uptrend |
| 1Y return | -6.1% | Lagged the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.18 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 28.1% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 58.0% | Strong big-investor interest | 30%+ is strong |
| Analyst target | ₹1,104.89 | 7.2% upside · 27 analysts | 8%+ upside |
Questions about MAXHEALTH
What is the share price of Max Healthcare Institute Limited (MAXHEALTH) today?
MAXHEALTH last traded at ₹1,030.90 (+2.08% on the day) on the NSE. Its 52-week range is ₹797.00 to ₹1,185.40. Prices are delayed and come from Yahoo Finance.
Is MAXHEALTH a good stock for the long term?
StockLens rates MAXHEALTH 4.6 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: revenue growth, low debt, uptrend. Concerns: expensive vs peers, falling profits, bearish moving averages.
Is MAXHEALTH share overvalued?
MAXHEALTH trades at a P/E of 73.0 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 8.86.
Is MAXHEALTH good for short-term trading?
The trade bias for the next few weeks is "No clear edge": Signals conflict. Sit it out or keep positions small. The price is 2.1% above its 200-day average and 14-day RSI is 76.
Which stocks are similar to MAXHEALTH?
Similar Pharma & Healthcare stocks of comparable size include Aurobindo Pharma, Cipla, Lupin, Dr. Reddy's Laboratories, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.
About Max Healthcare Institute Limited
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, bone marrow transplant, bariatric/weight loss surgery, gynecology, minimal access/laparoscopic surgery, eye care/ophthalmology, robotic surgery, paediatrics, nephrology, liver and biliary sciences, gastroenterology and GI surgery, internal medicine, organ transplants, and plastic and reconstructive surgery. The company also provides Max@Home, a platform that offers health and wellness services at home; and Max Lab, which provides diagnostic testing services to patients. In addition, it offers organ and tissue donation, preventive health checks, ambulance and immigration, air ambulance, and insurance and TPA services. The company provides healthcare services through a network of primary care clinics, multi-specialty hospitals/medical centres, and super-specialty hospital facilities. Max Healthcare Institute Limited was incorporated in 2001 and is based in Gurugram, India.
Stocks similar to MAXHEALTH
- Aurobindo Pharma share price
- Cipla share price
- Lupin share price
- Dr. Reddy's Laboratories share price
- Zydus Lifesciences share price
- Apollo Hospitals share price
Compare MAXHEALTH with AUROPHARMA, CIPLA, LUPIN
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.